Explore the potential of protein design with the new deep learning approach from Chongqing University to enhance binding ...

Learn how radiopharmaceuticals are transforming nuclear medicine and cancer therapy through targeted diagnostics and ...

Learn how antibody to payload design is crucial for advancing ADC technology in oncology and beyond with expert insights.

Forget the buzzwords – SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems. This year, the focus wasn’t on bold ...

What if a single hormone could control appetite in two entirely different ways? Professor Stefan Trapp of University College London reveals how GLP-1’s dual role in the brain and gut could transform ...

While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is ...

You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and ...

Scientists have developed a 3D liver model, known as the periportal assembloid. This model replicates the liver’s complex structure and bile transport system, enabling more precise study of disease ...

Explore how multimodal AI is transforming drug development by integrating diverse data sources to accelerate discovery.

Dr Nicolas Camper at CDMO Abzena and colleagues offer insight into the landscape of antibody-drug conjugates and how the therapy is evolving. Antibody-drug conjugates (ADCs) have been a groundbreaking ...

This Q&A with Dr Hernan A Bazan, CEO and Co-founder of South Rampart Pharma, Inc, discusses the potential merits of novel non-opioid analgesic SPR-001, which is Phase II-ready for acute and ...